In normal or reactive processes, a bimodal distribution of
kappa and lambda-positive B cells is present in a ratio of
approximately 1.5:1. Immunophenotyping using
multiparameter analysis (simultaneous staining with a pan
B-cell marker and anti-immunoglobulin light chain
antibodies) is a rapid and specific method for detecting
and confirming the presence of neoplastic B-cell
disorders.
Chronic lymphocytic leukemia (CLL) is a clonal
lymphoproliferative disorder usually of B-cell origin
(95%), that has been traditionally diagnosed using
clinical and morphologic criteria. Incorporation of
immunophenotypic features into the diagnostic criteria is
helpful in separating common B-cell CLL from other
lymphoproliferative disorders. Detection of karyotypic
abnormalities is useful in assessing prognosis. Lymphocytes
in B-CLL coexpress CD19, CD20, and CD23 pan B-cell
antigens, CD5, pan T-cell antigen, and a single
immunoglobulin light chain, kappa or lambda. CD10 (CALLA)
expression is usually absent. Mantle cell lymphoma is
distinguished from CLL by absent or very dim expression of
CD23.
Lymphomas are biologically complex neoplasms of the
immune system. Numerous classification schemes have been
developed based on morphologic features. This limited
approach is often unreliable. Immunophenotyping, by flow
cytometry and/or immunohistochemistry, has emerged as a
valuable adjunct to conventional morphologic diagnosis and
classification. Flow cytometry offers the advantage of
rapid multiparameter analysis. Combining light scatter
characteristics with patterns of antigen expression and DNA
content provides biological information that is useful in
making a diagnosis and assessing prognosis. Various gating
strategies can be employed to enhance the detection of
minor populations, thus providing a level of sensitivity
comparable to molecular methods (gene rearrangement
studies).
T-cell CLL, unlike B-CLL, is associated with
rapid onset, an aggressive clinical course poorly
responsive to therapy and decreased survival.
Immunophenotyping, in the majority of cases, demonstrates
texpression of CD3 (a pan T-cell antigen), and CD4 (the
helper cell antigen). CD8 (the suppressor/cytotoxic cell
antigen) is usually not expressed. Genotyping demonstrates
a clonal rearrangement of the T-cell receptor gene.
Large granular lymphocyte (LGL) proliferations can be
divided into T-cell and natural killer (NK) cell subsets by
immunophenotyping. The more common T-cell type expresses
CD3, a pan T-cell antigen and CD8, the suppressor/cytotoxic
cell antigen. Genotyping demonstrates a rearrangement of
the T-cell receptor gene. The NK cell type is relatively
rare and expresses CD2 and CD16 and/or CD56. CD3
expression is absent. Genotyping demonstrates a germline
configuration of the T-cell receptor gene.
In S'ezary syndrome, the neoplastic lymphocytes aer T cells
with a helper cell phenotype. Expression of CD7, a pan
T-cell antigen, is absent and is useful in distinguishing
the neoplastic cells from normal T-helper cells.
Genotyping demonstrates a clonal rearrangement of the
T-cell receptor gene.
In adult T-cell leukemia/lymphoma, the neoplastic
lymphocytes are T-cells with a helper cell phenotype.
Expression of CD3, CD4, and CD25 is present. Expression of
CD7 is absent. Genotyping demonstrates a clonal
rearrangement of the T-cell receptor gene.
Detection of a B-cell population coexpressing CD22, CD11c,
adn CD25 is useful in establishing a diagnosis of hairy
cell leukemia when used in conjunction with morphology and
cytochemistry. Immunophenotyping by flow cytometry is a
sensitive method for detecting residual or recurrent
disease in the peripheral blood of patients with an
established diagnosis.
Detection of a population of cells expressing CD38 and
CD138 in the peripheral blood is useful in establishing a
diagnosis of plasma cell leukemia when used in conjunction
with morphology.
Lineage assignment in acute leukemia is necessary for
selecting appropriate therapy and is useful in assessing
prognosis.
Multiparameter analysis using four-color immunophenotyping
techniques is a rapid and specific method of assigning
lineage in acute leukemia.
This profile is also useful in distinguishing lymphoid from
myeloid blast crisis in CML and immunophenotyping
lymphoblastic lymphoma in blood or bone marrow.
Immunophenotyping and cytogenetic analysis are increasingly
being used to supplement the traditional methods
(morphology and cytochemistry) of classifying acute
leukemias and to provide prognostic information. Acute
lymphoblastic leukemia (ALL) can be classified into
undifferentiated null T-and B-cell lineages. In all
of B-cell lineage, expression of CD10 (CALLA) is a
favorable prognostic factor. Acute myelogenous leukemias
(AML) are a heterogeneous group. In cases where morphology
and cytochemical staining is equivocal, immunophenotyping
can be useful. Immunophenotyping is particularly useful in
classifying megakaryoblastic leukemia (FABM7). A
combination of characteristic light scattering properties
and myeloid phenotype can suggest a diagnosis of acute
promyelocytic leukemia (FABM3). Confirmation of the
retinoic acid receptor gene rearrangement by cytogenetic or
molecular methods is recommended. See PML-RARA Transcript Detection
for Acute Promyelocytic Leukemia, Qualitative [480491],
Chromosome Analysis,
Leukemia/Lymphoma [052001], and related Fluorescence in situ
Hybridization (FISH), Oncology [510362].